Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of Pumitamig alone or combined with other drugs in people with advanced Renal Cell Carcinoma RCC, a type of kidney cancer. This study is in phases 1 and 2 and is designed to better understand how these treatments work in patients with both clear cell and non-clear cell RCC, focusing on those with locally advanced or metastatic disease. Participants will receive Pumitamig alone or in combination with other agents such as Ipilimumab, Cabozantinib, or Casdatifan. The study includes multiple experimental treatment groups, where specific doses are given on specified days. The treatments are administered in a randomized, open-label manner, and the study aims to observe responses over time. The trial includes up to approximately two years of treatment monitoring, with some outcome measures extending up to four years from randomization. Throughout the study, participants will be assessed for side effects, treatment response, and disease progression using established criteria. Researchers will monitor adverse events, dose-limiting toxicities, and serious side effects. Evaluations include measuring tumor response by imaging and clinical assessments. The study also tracks progression-free survival and duration of response. Follow-up continues for up to two years after treatment completion to understand long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are evaluating treatments for amblyopia in children aged 4 to 7 years. The study compares watching dichoptic movies or shows using the Luminopia virtual reality headset for 1 hour a day, 6 days a week, against patching the fellow eye for 2 hours a day, 7 days a week. The goal is to see if the dichoptic treatment is not worse than patching in improving distance visual acuity in the amblyopic eye over 26 weeks. Participants are randomly assigned to one of two groups the Luminopia group, who watch dichoptic content through a headset daily, or the patching group, who wear an eye patch for specified times. After 26 weeks, if participants in the patching group do not show sufficient improvement, they are offered the Luminopia therapy with follow-up visits at weeks 39 and 52. Those who do not qualify for this extension end the study after 26 weeks. During the study, participants undergo clinical assessments at 13 and 26 weeks post-randomization to measure changes in vision. Follow-up visits are scheduled for participants who switch to Luminopia after patching if needed. Researchers monitor adherence to treatment, visual acuity changes, and any safety concerns throughout the trial, which lasts up to 52 weeks for some participants.
Actively Recruiting
This research is evaluating dichoptic treatments for children aged 8 to 12 years with amblyopia, a vision condition. Participants will be randomly assigned to one of three groups wearing the Luminopia headset to watch dichoptic movies, using the Vivid Vision headset to play dichoptic games, or continuing with optical correction alone if needed. The study aims to compare these approaches to improve visual acuity in the amblyopic eye. Participants assigned to the Luminopia group will watch dichoptic movies or shows for one hour daily, six days per week, while using their prescribed optical correction if needed. The Vivid Vision group will play dichoptic games using a virtual reality headset for approximately 25 minutes daily, six days per week, also with optical correction if required. The third group will continue full-time optical correction alone. At 18 weeks, those initially on optical correction alone who show significant vision difference may be offered a chance to try either dichoptic treatment, with follow-up visits extending to 36 weeks. Throughout the study, participants will have clinical assessments at 9 and 18 weeks after starting treatment. Those switching to dichoptic therapy after 18 weeks will have additional visits at 27 and 36 weeks. Researchers will measure changes in visual acuity of the amblyopic eye and assess quality of life through questionnaires. The study includes monitoring adherence to treatments and continues for up to 36 weeks for some participants, with safety and effectiveness evaluated during follow-up visits.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.